Heart Failure Outcomes Captured by Adverse Event Reporting in Participants with Type 2 Diabetes and Atherosclerotic Cardiovascular Disease: Observations from the VERTIS CV Trial
Ambarish Pandey(Cleveland Clinic), Christopher P. Cannon(Brigham and Women's Hospital), David Z.I. Cherney(University Health Network), Samuel Dagogo‐Jack(University of Tennessee Health Science Center), Robert Frederich(Pfizer (United States)), Urszula Masiukiewicz(Pfizer (United States)), Willy Wynant(Syneos Health (United States)), Nilo B. Cater(Pfizer (United States)), Francesco Cosentino, Ahmed A. Kolkailah(Southwestern Medical Center), Richard E. Pratley(Translational Research Institute for Metabolism and Diabetes), Darren K. McGuire(Parkland Health & Hospital System), James P. Mancuso(Pfizer (United States)), Ira Gantz(Merck & Co., Inc., Rahway, NJ, USA (United States))
Cited by 1
Related Papers
Heart Disease and Stroke Statistics—2019 Update: A Report From the American Heart Association
|Circulation|2019|9.1k
Heart Disease and Stroke Statistics—2018 Update: A Report From the American Heart Association
|Circulation|2018|7.2k
Impact of diabetes on the effects of sodium glucose co-transporter-2 inhibitors on kidney outcomes: collaborative meta-analysis of large placebo-controlled trials
|The Lancet|2022|969